A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:36
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
[31]   Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin [J].
Kawamori, Ryuzo ;
Kaku, Kohei ;
Hanafusa, Toshiaki ;
Ioriya, Katsuhisa ;
Kageyama, Shigeru ;
Hotta, Nigishi .
JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (02) :253-259
[32]   Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin [J].
Ba, Jianming ;
Han, Ping ;
Yuan, Guoyue ;
Mo, Zhaohui ;
Pan, Changyu ;
Wu, Fan ;
Xu, Lei ;
Hanson, Mary E. ;
Engel, Samuel S. ;
Shankar, R. Ravi .
JOURNAL OF DIABETES, 2017, 9 (07) :667-676
[33]   Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study [J].
Takai, Masahiko ;
Ishikawa, Masashi ;
Maeda, Hajime ;
Kanamori, Akira ;
Kubota, Akira ;
Amemiya, Hikaru ;
Iizuka, Takashi ;
Iemitsu, Kotaro ;
Iwasaki, Tomoyuki ;
Uehara, Goro ;
Umezawa, Shinichi ;
Obana, Mitsuo ;
Kaneshige, Hideaki ;
Kaneshiro, Mizuki ;
Kawata, Takehiro ;
Sasai, Nobuo ;
Saito, Tatsuya ;
Takuma, Tetsuo ;
Takeda, Hiroshi ;
Tanaka, Keiji ;
Tsurui, Nobuaki ;
Nakajima, Shigeru ;
Hoshino, Kazuhiko ;
Honda, Shin ;
Machimura, Hideo ;
Matoba, Kiyokazu ;
Minagawa, Fuyuki ;
Minami, Nobuaki ;
Miyairi, Yukiko ;
Mokubo, Atsuko ;
Motomiya, Tetsuya ;
Waseda, Manabu ;
Miyakawa, Masaaki ;
Naka, Yoshikazu ;
Terauchi, Yasuo ;
Tanaka, Yasushi ;
Matsuba, Ikuro .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) :E30-E33
[34]   Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2-Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes [J].
Anton, Irina Claudia ;
Mititelu-Tartau, Liliana ;
Popa, Eliza Gratiela ;
Poroch, Mihaela ;
Poroch, Vladimir ;
Pintilei, Delia Reurean ;
Botnariu, Gina Eosefina .
HEALTHCARE, 2022, 10 (07)
[35]   Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial [J].
Guo Qiang ;
Zhang Hengyao ;
Li Mindian ;
Zhao Ziyi ;
Luo Yunlin ;
Luo Yulei ;
Cao Wenzhai ;
Zhao Huan ;
Zhu Ranran ;
Lei Xingxing ;
Chen Huizhen ;
Gan Huakui ;
Zuo Zhihuang ;
Chen Qi ;
Shi Cuimei ;
Zhang Xinli ;
Guo Jian ;
Zhong Sen ;
Chen Qiu .
JournalofTraditionalChineseMedicine, 2016, 36 (05) :640-648
[36]   Efficacy and safety of Sancai powder in patients with type 2 diabetes mellitus: a randomized controlled trial [J].
Guo Qiang ;
Zhang Hengyao ;
Li Mindian ;
Zhao Ziyi ;
Luo Yunlin ;
Luo Yulei ;
Cao Wenzhai ;
Zhao Huan ;
Zhu Ranran ;
Lei Xingxing ;
Chen Huizhen ;
Gan Huakui ;
Zuo Zhihuang ;
Chen Qi ;
Shi Cuimei ;
Zhang Xinli ;
Guo Jian ;
Zhong Sen ;
Chen Qiu .
JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2016, 36 (05) :640-648
[37]   Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial [J].
Yang, Wenying ;
Han, Ping ;
Min, Kyung-Wan ;
Wang, Bei ;
Mansfield, Traci ;
T'Joen, Caroline ;
Iqbal, Nayyar ;
Johnsson, Eva ;
Ptaszynska, Agata .
JOURNAL OF DIABETES, 2016, 8 (06) :796-808
[38]   Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study [J].
Shigiyama, Fumika ;
Kumashiro, Naoki ;
Fuchigami, Ayako ;
Hirose, Takahisa .
CARDIOVASCULAR DIABETOLOGY, 2018, 17
[39]   Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR) [J].
Ayako Fuchigami ;
Fumika Shigiyama ;
Toru Kitazawa ;
Yosuke Okada ;
Takamasa Ichijo ;
Mariko Higa ;
Toru Hiyoshi ;
Ikuo Inoue ;
Kaoru Iso ;
Hidenori Yoshii ;
Takahisa Hirose ;
Naoki Kumashiro .
Cardiovascular Diabetology, 19
[40]   Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial [J].
F. J. Lavalle-González ;
A. Januszewicz ;
J. Davidson ;
C. Tong ;
R. Qiu ;
W. Canovatchel ;
G. Meininger .
Diabetologia, 2013, 56 :2582-2592